| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hiroshi Ito, Harumasa Takano, Ryosuke Arakawa, Hidehiko Takahashi, Fumitoshi Kodaka, Keisuke Takahata, Tsuyoshi Nogami, Masayuki Suzuki, Tetsuya Suhar. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. PloS one. vol 7. issue 9. 2013-02-20. PMID:23029533. |
a significant negative correlation was observed between baseline dopamine synthesis capacity and changes in dopamine synthesis capacity by aripiprazole, indicating that this antipsychotic appears to stabilize dopamine synthesis capacity. |
2013-02-20 |
2023-08-12 |
human |
| T Ishima, M Iyo, K Hashimot. Neurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole. Translational psychiatry. vol 2. 2013-02-19. PMID:23047241. |
the 5-ht(1a) receptor antagonist way-100635, but not the dopamine d(2) receptor antagonist sulpiride, blocked the effects of aripiprazole, although, only partially. |
2013-02-19 |
2023-08-12 |
Not clear |
| Shigenori Tadokoro, Naoe Okamura, Yoshimoto Sekine, Nobuhisa Kanahara, Kenji Hashimoto, Masaomi Iy. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophrenia bulletin. vol 38. issue 5. 2013-02-04. PMID:21402722. |
chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. |
2013-02-04 |
2023-08-12 |
Not clear |
| Shigenori Tadokoro, Naoe Okamura, Yoshimoto Sekine, Nobuhisa Kanahara, Kenji Hashimoto, Masaomi Iy. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophrenia bulletin. vol 38. issue 5. 2013-02-04. PMID:21402722. |
we investigated the chronic effects of aripiprazole (ari) on dopamine sensitivity. |
2013-02-04 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukori, Ayako Kaneda, Norio Sugawara, Tetsu Tomita, Sunao Kanek. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. Journal of psychopharmacology (Oxford, England). vol 26. issue 6. 2013-01-15. PMID:21616975. |
aripiprazole, which is a partial dopamine d2 receptor agonist, may have an impact on cognitive dysfunction in patients with schizophrenia. |
2013-01-15 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukori, Ayako Kaneda, Norio Sugawara, Tetsu Tomita, Sunao Kanek. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. Journal of psychopharmacology (Oxford, England). vol 26. issue 6. 2013-01-15. PMID:21616975. |
it is likely that these effects are due to the dopamine d2 antagonistic effect of aripiprazole. |
2013-01-15 |
2023-08-12 |
Not clear |
| Claire Chevreuil, Elisabeth Polard, Eric Lemonnier, Paul Guillemot, Danièle Bentué-Ferre. [Aripiprazole use in children and adolescent psychiatric patients]. Therapie. vol 66. issue 2. 2013-01-04. PMID:21635859. |
its mechanism of action is different as aripiprazole is a partial dopamine d(2) and serotonin 5-ht(1a) receptor agonist and 5-ht(2a) receptor antagonist. |
2013-01-04 |
2023-08-12 |
Not clear |
| M Brunetti, L Di Tizio, S Dezi, G Pozzi, P Grandinetti, G Martinott. Aripiprazole, alcohol and substance abuse: a review. European review for medical and pharmacological sciences. vol 16. issue 10. 2012-12-20. PMID:23104650. |
the use of aripiprazole and partial dopamine agonists could represent a novel strategy for normalizing dopamine neurotransmission. |
2012-12-20 |
2023-08-12 |
Not clear |
| Eiji Kirin. Efficacy and safety of aripiprazole in child and adolescent patients. European child & adolescent psychiatry. vol 21. issue 7. 2012-11-26. PMID:22447196. |
aripiprazole (apz) has a unique pharmacological profile, as a partial agonist at the dopamine d2 and serotonin 5ht1a receptors and an antagonist at the serotonin 5ht2a receptor; this drug has few side effects (such as extrapyramidal syndrome, hyperprolactinemia, weight gain, metabolic disorders, and sedation) which are typical problems with other antipsychotic drugs. |
2012-11-26 |
2023-08-12 |
Not clear |
| Jyotik T Bhachec. Aripiprazole-induced oculogyric crisis (acute dystonia). Journal of pharmacology & pharmacotherapeutics. vol 3. issue 3. 2012-11-07. PMID:23129969. |
aripiprazole is the third generation atypical antipsychotic and a dopamine serotonin system stabilizer (dss) effective against positive and negative symptoms of schizophrenia. |
2012-11-07 |
2023-08-12 |
Not clear |
| Keisuke Takahata, Hiroshi Ito, Harumasa Takano, Ryosuke Arakawa, Hironobu Fujiwara, Yasuyuki Kimura, Fumitoshi Kodaka, Takeshi Sasaki, Tsuyoshi Nogami, Masayuki Suzuki, Tomohisa Nagashima, Hitoshi Shimada, Motoichiro Kato, Masaru Mimura, Tetsuya Suhar. Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457. Psychopharmacology. vol 222. issue 1. 2012-10-22. PMID:22237854. |
striatal and extrastriatal dopamine d₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹c]raclopride and [¹¹c]flb457. |
2012-10-22 |
2023-08-12 |
human |
| Keisuke Takahata, Hiroshi Ito, Harumasa Takano, Ryosuke Arakawa, Hironobu Fujiwara, Yasuyuki Kimura, Fumitoshi Kodaka, Takeshi Sasaki, Tsuyoshi Nogami, Masayuki Suzuki, Tomohisa Nagashima, Hitoshi Shimada, Motoichiro Kato, Masaru Mimura, Tetsuya Suhar. Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457. Psychopharmacology. vol 222. issue 1. 2012-10-22. PMID:22237854. |
in the present study, we focused on aripiprazole, which has a unique pharmacological profile with partial agonism at dopamine d₂ receptors and the minimal risk of extrapyramidal side effects. |
2012-10-22 |
2023-08-12 |
human |
| Keisuke Takahata, Hiroshi Ito, Harumasa Takano, Ryosuke Arakawa, Hironobu Fujiwara, Yasuyuki Kimura, Fumitoshi Kodaka, Takeshi Sasaki, Tsuyoshi Nogami, Masayuki Suzuki, Tomohisa Nagashima, Hitoshi Shimada, Motoichiro Kato, Masaru Mimura, Tetsuya Suhar. Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457. Psychopharmacology. vol 222. issue 1. 2012-10-22. PMID:22237854. |
previous positron emission tomography (pet) studies using high-affinity radioligands for dopamine d₂ receptors have reported inconsistent results regarding regional differences of dopamine d₂ receptor occupancy by aripiprazole. |
2012-10-22 |
2023-08-12 |
human |
| Tsuyoshi Sasaki, Tasuku Hashimoto, Tomihisa Niitsu, Nobuhisa Kanahara, Masaomi Iy. Treatment of refractory catatonic schizophrenia with low dose aripiprazole. Annals of general psychiatry. vol 11. issue 1. 2012-10-18. PMID:22553911. |
the mechanisms underlying the effects of low-dose aripiprazole in this case remain unclear, but unlike other antipsychotics, aripiprazole is a dopamine d2 partial agonist. |
2012-10-18 |
2023-08-12 |
Not clear |
| William Winlow, Louise Profit, Paul Chris. Aripiprazole: the evidence of its therapeutic impact in schizophrenia. Core evidence. vol 1. issue 4. 2012-10-02. PMID:22496680. |
the dopamine partial agonist aripiprazole is compared with this ideal and with conventional antipsychotics, such as haloperidol, and with atypical antipsychotics. |
2012-10-02 |
2023-08-12 |
Not clear |
| John J O'Connor, John P Lowr. A comparison of the effects of the dopamine partial agonists aripiprazole and (-)-3-PPP with quinpirole on stimulated dopamine release in the rat striatum: Studies using fast cyclic voltammetry in vitro. European journal of pharmacology. vol 686. issue 1-3. 2012-10-02. PMID:22575523. |
a comparison of the effects of the dopamine partial agonists aripiprazole and (-)-3-ppp with quinpirole on stimulated dopamine release in the rat striatum: studies using fast cyclic voltammetry in vitro. |
2012-10-02 |
2023-08-12 |
rat |
| John J O'Connor, John P Lowr. A comparison of the effects of the dopamine partial agonists aripiprazole and (-)-3-PPP with quinpirole on stimulated dopamine release in the rat striatum: Studies using fast cyclic voltammetry in vitro. European journal of pharmacology. vol 686. issue 1-3. 2012-10-02. PMID:22575523. |
the effects of aripiprazole, (-)-(3-hydroxyphenyl)-n-n-propylpiperidine ((-)-3-ppp) and quinpirole on single and multiple pulse stimulated dopamine release were investigated using the technique of fast cyclic voltammetry (fcv) in isolated rat striatal slices. |
2012-10-02 |
2023-08-12 |
rat |
| John J O'Connor, John P Lowr. A comparison of the effects of the dopamine partial agonists aripiprazole and (-)-3-PPP with quinpirole on stimulated dopamine release in the rat striatum: Studies using fast cyclic voltammetry in vitro. European journal of pharmacology. vol 686. issue 1-3. 2012-10-02. PMID:22575523. |
aripiprazole and (-)-3-ppp had no significant effect on single pulse dopamine release at concentrations from 10nm to 10μm indicating low agonist activity. |
2012-10-02 |
2023-08-12 |
rat |
| John J O'Connor, John P Lowr. A comparison of the effects of the dopamine partial agonists aripiprazole and (-)-3-PPP with quinpirole on stimulated dopamine release in the rat striatum: Studies using fast cyclic voltammetry in vitro. European journal of pharmacology. vol 686. issue 1-3. 2012-10-02. PMID:22575523. |
the compounds failed to potentiate 5 pulse stimulated release of dopamine although inhibitory effects were seen at 10μm for aripiprazole. |
2012-10-02 |
2023-08-12 |
rat |
| Jin Mizushima, Keisuke Takahata, Noriko Kawashima, Motoichiro Kat. Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug. Annals of general psychiatry. vol 11. issue 1. 2012-10-02. PMID:22769562. |
in this article, we present a case of pd in whom the administration of the dopamine d2 partial agonistic antipsychotic drug aripiprazole improved dds symptoms such as craving and compulsive behavior without worsening of motor symptoms. |
2012-10-02 |
2023-08-12 |
Not clear |